title: Ovarian cancer treatment: The end of empiricism?
abstract: The diagnosis, investigation, and management of ovarian cancer are in a state of flux-balancing ever rapid advances in our understanding of its biology with 3 decades of clinical trials. Clinical trials that started with empirically driven selections have evolved in an evidence-informed manner to gradually improve outcome. Has this improved understanding of the biology and associated calls to action led to appropriate changes in therapy? In this review, the authors discuss incorporating emerging data on biology, combinations, dose, and scheduling of new and existing agents with patient preferences in the management of women with ovarian cancer.
authors.affiliation: Division of Medical Oncology and Hematology, Bras Family Drug Development Program, Princess Margaret Cancer Center, Toronto, Ontario, Canada.
authors.forename: Stephanie
authors.initials: S
authors.lastname: Lheureux
authors.affiliation: Division of Medical Oncology and Hematology, Bras Family Drug Development Program, Princess Margaret Cancer Center, Toronto, Ontario, Canada.
authors.forename: Katherine
authors.initials: K
authors.lastname: Karakasis
authors.affiliation: Cancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, Maryland.
authors.forename: Elise C
authors.initials: EC
authors.lastname: Kohn
authors.affiliation: Division of Medical Oncology and Hematology, Bras Family Drug Development Program, Princess Margaret Cancer Center, Toronto, Ontario, Canada.
authors.forename: Amit M
authors.initials: AM
authors.lastname: Oza
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D019317:Evidence-Based Medicine; D005260:Female; D006801:Humans; D010051:Ovarian Neoplasms / Q000188:drug therapy*
chemical_list: D000970:Antineoplastic Agents
keywords: biology; biomarkers; ovarian cancer; strategy; treatment